EGFR Inhibitor

5 Drugs classified under this drug class

EGFR Inhibitor, Kinase Inhibitor. Vandetanib 100 mg.
FC TABS: 30 x 100mg. Recom.
dose 300mg 1x dly. Pts. must be given
patient alert card and be informed of
risks Assess QTc interval prior to init.
tmt. Can reduce dosage if necess.
See lit.
Tmt. aggressive and sympt. medullary
thyroid cancer (MTC) in pts. with
unresectable locally advanced or
metastatic dis. Pts.in whom Rearranged
during Transfection (RET) mutation is not
known or is neg., a possible lower benefit
should be taken into account. See lit.
C/I: Hypersens. to active subst. or excip;
congenital long QTc syndrome; pts. with
QTc interval > 480msec.; concomit. use
of arsenic, cisapride,erythromycin, iv.
toremifene, mizolastine moxifloxacin,
class Ia and III antiarrhythmics. See lit.

EGFR Inhibitor, Monoclonal Antibody. Cetuximab 5 mg/ml.
VIAL (I.V. infus.): 20 ml, 100 ml. Initial: 400 mg/m², foll. by 1 x wkly. dose of 250 mg/m². See lit.
Tmt. of pts. with (EGFR)-expressing, RAS
wild-type metast. colorectal canc. in
comb. with irinotecan-based chemot., in
1st -line in comb. with FOLFOX, as a single
agent in pts. who have failed oxaliplatin and irinotecan- based ther. and who
are intoler. to irinotecan. Tmt. of pts. with
squamous cell canc. of the head and neck
(SCCHN), in comb. with rad. ther. for
local. advanced dis., in comb. with
platinum-based chemo. for recur. and/
or metast. dis., as a single agent after fail.
of platinum-based chemo. for recur.
and/or metast. dis.
C/I: Severe hypersens, The comb. with
oxaliplatin-cont. chemot. is contraindic.
for pts. with mutant RAS metast.
colorectal canc. (mCRC) or for whom
RAS mCRC status is unknown.
Contraind. for concom. used chemot.
agents or rad. ther. must be
considered before init. of comb. tmt.

EGFR Inhibitor. Gefitinib 250 mg.
F.C. TAB.:30. 250 mg (1 tab.)×1/d with / without food. See lit.
Tmt. of  adult pts. with local. advanced or metastat. Non‐small cell lung cancer (NSCLC) with activat. mutations of EGFR‐TK.
C/I: Hypersens.
Lact.

 

EGFR Inhibitor. Gefitinib 250 mg.
F.C. TABS: 30. Swall. whole 1 tab dly, with/
out food, as monother. in advanced
non-small-cell lung cancer (NSCLC)
prev. receiv. tmt. with cytotox.
chemother. Not recommend. child/
adolesc. No adjust reqd. in pt. age,
bdy. wt., gender, ethnicity, ren. funct.
Poorly tol. diarrh./skin adverse drug reacts: Brief (up to 14 days) ther.
interrupt foll. by reinstate 250 mg
dose.
Tmt. local advanced/metastat. NSCLC
who have prev. received chemother.
C/I: Hypersens.

EGFR Inhibitor, MET inhibitor, Monoclonal Antibody. amivantamab 50 mg/ml.
Vial, conc. for sol. for inf. 1 vial 350 mg/ 7 ml
Administer via peripheral line for Week 1 Day 1 and 2 and Week 2 to reduce the risk of infus. related reactions.
When administering in combin. with carboplatin and pemetrexed, infuse pemetrexed first, carboplatin second, and amivantamab last.
When administering in combin. with lazertinib, administer lazertinib orally any time before the amivantamab infus.
When administering in combin. with lazertinib, administer anticoagulant prophylaxis to prevent venous thromboembolic (VTE) events for the first 4 mo of tmt. See prescrib. info
First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substit. Mutat.
First-line tmt. of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substit. mutat., as detected by an approved test, in combin. with Lazertinib.
Previously Treated NSCLC with EGFR Exon 20 Insertion Mutat.
Tmt of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutat., as detected by an approved test, whose dis. has progress. on or after platinum-based chemother.
First line tmt. of NSCLC with EGFR Exon 20 Insertion Mutat.
First-line tmt of adults with locally adv. (not amenable to curative ther.) or metast. NSCLC with activating EGFR Exon 20 insertion mutat. in combin. with carboplatin and pemetrexed.
Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substit. Mutat.
Tmt. of adults with locally adv. or metast. non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substit. mutat., whose dis. has progressed on or after tmt. with an EGFR tyrosine kinase inhibitor (TKI), in combin. with carboplatin and pemetrexed.
C/I:  Hypersens.